The
parties have entered a
non-binding Letter of Intent
RA'ANANA, Israel, Feb. 8, 2024
/PRNewswire/ -- Inspira Technologies OXY BHN
Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or
"Inspira"), a pioneer in life support technology with a vision
to supersede traditional mechanical ventilators, has announced the
signing of a non-binding Letter of Intent (LOI) with Shamir Medical
Center (Assaf Harofeh), a renowned
healthcare institution in central Israel. The Company plans to extend
collaborations with further leading Israeli medical centers as part
of a wider clinical deployment strategy.
The LOI solidifies the mutual commitment of both parties to
assess the integration and performance of the INSPIRA™ ART100
device ("Device) within Shamir Medical Center's clinical
environment. This includes evaluating the device's fit with the
hospital's clinical needs, efficiency in workflow, and overall
impact on healthcare delivery. The hospital will procure all
required disposables for operating the Devices as part of the LOI.
Inspira will gain access to device operation data and user
experience in a real-life clinical setting. The evaluation will be
led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at
Shamir Medical Center and a leading pioneer of critical care
medicine in Israel. The
progression of this LOI hinges on the AMAR (medical devices and
accessories) approval by the Israeli Ministry of Health for the
Device, and the subsequent formalization of a detailed definitive
evaluation agreement between the parties.
Joe Hayon, President of
Inspira Technologies, stated: "With the anticipated
U.S. Food and Drug Administration (FDA) approval on the horizon, I
am confident that this prospective collaboration with Shamir
Medical Center will enhance the efficacy of life-support care and
establish a pathway for its adoption in both local and
international markets."
About Shamir Medical Center (Assaf
Harofeh)
Shamir Medical Center (Assaf
Harofeh), Israel's
fourth-largest government hospital, is a beacon of advanced medical
care, serving over 1 million residents in the central region. Known
for its state-of-the-art facilities and commitment to medical
innovation, the hospital is currently transforming to meet the
growing population's needs. Renowned for its excellence in critical
care, the Intensive Care Unit (ICU) at Shamir Medical Center is a
model of innovation, particularly in Extracorporeal Membrane
Oxygenation (ECMO) expertise. With a focus on patient-centered
interventions, the ICU leads in awake ECMO treatment, demonstrating
a dedication to advancing critical care during the COVID-19
pandemic. Overall, Shamir Medical Center remains at the forefront
of medical excellence, contributing significantly to the global
medical community through publications, ongoing research projects,
and a commitment to pushing the boundaries of critical care.
About Inspira Technologies OXY BHN Ltd.
Inspira Technologies is leading the way in transforming
life-support care. Its innovative solutions are paving the way for
direct blood oxygenation, bypassing the lungs, and potentially
reducing the need for traditional mechanical ventilation. Beyond
this, the Company is committed to advancing blood circulation
technology and incorporating AI-driven monitoring systems. These
advancements are part of its strategy to offer more
patient-focused, data-informed care. The integration of these
technologies signifies the potential to enhance patient outcomes
and streamline hospital operations, marking a new era in
respiratory care.
For more information, please visit our corporate website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements under US Federal securities laws. These forward-looking
statements and their implications are based only on the current
expectations of the management of the Company. They are subject to
several factors and uncertainties that could cause results to
differ materially from those described in the forward-looking
statements. For example, the Company uses forward-looking
statements when it discusses the potential for executing the
definitive agreement, that it plans to extend collaborations with
further leading Israeli medical centers as part of a wider clinical
deployment strategy, the proposed evaluation of the Device by
Shamir Medical Center, the expected timing of FDA approval of the
Device, that the progress of the LOI hinges on the AMAR approval by
the Israeli Ministry of Health for the Device, and the subsequent
formalization of a detailed definitive evaluation agreement between
the parties, the belief that the prospective collaboration with
Shamir Medical Center will enhance the efficacy of life-support
care and establish a pathway for its adoption in both local and
international markets and its vision to supersede traditional
mechanical ventilators. Except as otherwise required by law, the
Company undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or
circumstances after the date hereof or the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2022,
filed with the SEC, which is available on the SEC's website,
www.sec.gov.
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2023 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-technologies-collaborates-with-a-leading-israeli-medical-center-for-clinical-evaluation-of-inspira-art-device-302057580.html
SOURCE Inspira Technologies